Neoadjuvant nab-paclitaxel and gemcitabine in borderline resectable or locally advanced unresectable pancreatic adenocarcinoma in patients who are ineligible for FOLFIRINOX

Shawn L. Peterson, Muhammad Husnain, Terri Pollack, Agustin Pimentel, Arturo Loaiza-Bonilla, Colleen Westendorf-Overley, Kelley Ratermann, Lowell Anthony, Philip Desimone, Gaurav Goel, Mahesh Kudrimoti, Sean Dineen, Ching Wei D. Tzeng, Peter J. Hosein

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Background/Aim: Combination nab-paclitaxel/ gemcitabine (AG) is superior to gemcitabine in patients with metastatic pancreatic cancer (PC). There are limited data for AG in borderline resectable (BR) or locally advanced pancreatic cancer (LAPC). Herein, we report our experience with neoadjuvant AG for BR/LAPC in patients ineligible for FOLFIRINOX. Patients and Methods: This retrospective series, included patients with BR/LAPC who received AG as neoadjuvant therapy for 3-4 months followed by radiation, then re-evaluation for surgery. Results: Between 10/2013-2/2018, 32 patients (22 BR, 10 LAPC) were treated with this approach. Median age was 70 years. Nine patients were converted to resectability by imaging; six had R0 resections (19%), five (16%) achieved a partial response and 24 (75%) had stable disease. Conclusion: In this small series, the R0 resection rate and response rate were 19% and 16% respectively. These data suggest that neoadjuvant AG may be an alternate option for patients ineligible for FOLFIRINOX.

Original languageEnglish (US)
Pages (from-to)4035-4039
Number of pages5
JournalAnticancer research
Volume38
Issue number7
DOIs
StatePublished - Jul 2018

Keywords

  • Gemcitabine
  • Locally advanced
  • Nab-paclitaxel
  • Neoadjuvant
  • Pancreatic cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Neoadjuvant nab-paclitaxel and gemcitabine in borderline resectable or locally advanced unresectable pancreatic adenocarcinoma in patients who are ineligible for FOLFIRINOX'. Together they form a unique fingerprint.

  • Cite this

    Peterson, S. L., Husnain, M., Pollack, T., Pimentel, A., Loaiza-Bonilla, A., Westendorf-Overley, C., Ratermann, K., Anthony, L., Desimone, P., Goel, G., Kudrimoti, M., Dineen, S., Tzeng, C. W. D., & Hosein, P. J. (2018). Neoadjuvant nab-paclitaxel and gemcitabine in borderline resectable or locally advanced unresectable pancreatic adenocarcinoma in patients who are ineligible for FOLFIRINOX. Anticancer research, 38(7), 4035-4039. https://doi.org/10.21873/anticanres.12692